AngioAI+™ Platform
Diagnosis and management of Coronary Artery Disease (CAD) and Coronary Microvascular Disease (CMD)
Key Facts
About AngioInsight
AngioInsight is a private, pre-revenue biotech company pioneering AI-powered diagnostic software for cardiovascular disease. Its core investigational platform, AngioAI+™, analyzes routine angiograms to provide combined assessments for epicardial blockages (CAD) and microvascular dysfunction (CMD), addressing a significant unmet need in cardiology, particularly for patients with ischemia but no obstructive coronary arteries (INOCA). The company is led by a seasoned team with expertise in AI/ML, cardiovascular medicine, and medical device regulation, positioning it to tackle the diagnostic challenges and subjective visual assessments that currently dominate angiography.
View full company profile